Latest Rankings by Database

We update our monthly rankings using the most recent year of data extracted from each database.
These rankings offer insight into the scale of our DPC and insurer databases—the largest of their kind in Japan.

These rankings are aggregated using MDV analyzer, based on MDV’s medical databases. The DPC data covers approximately 28% of acute care (DPC) hospitals in Japan* and is notable for its extensive information on elderly patients.
The health insurance data features traceability across medical facilities,covering data from both the National Health Insurance and the Medical Care System For The Elderly.
*As of December 1, 2023.

MDV Database Overview

2025.10.02

Top 10 Prescription Drugs by Sales Amount Among Rheumatoid Arthritis Patient

DPC Data (August 2024-July 2025)
	Product Name	Actual Number of Patients	Number of Cases	Total Cost (JPY)
1	Actemra	12,764	92,771	8,685,207,930
2	Orencia	6,320	39,305	6,902,735,986
3	Simponi	4,560	28,779	6,161,837,408
4	Rinvoq	4,201	24,380	3,712,284,103
5	Olumiant	3,764	22,613	3,306,787,908
6	Humira	2,223	10,614	2,491,050,920
7	Ultomiris	64	305	2,085,552,600
8	Ofev	1,137	10,549	2,084,963,355
9	Kevzara	2,477	13,026	2,080,109,608
10	Jyseleca	2,565	14,215	2,026,028,401

Health Insurance Data (July 2024-June 2025)
	Product Name	Actual Number of Patients	Number of Cases	Total Cost (JPY)
1	Actemra	2,207	15,416	1,307,478,909
2	Simponi	624	3,383	705,041,841
3	Humira	576	2,827	535,741,860
4	Rinvoq	577	2,739	512,458,672
5	Orencia	540	3,163	493,124,952
6	Olumiant	512	2,470	480,199,825
7	Cimzia	383	1,712	346,464,052
8	Etanercept BS (MA)	1,350	7,808	332,022,643
9	Enbrel	572	3,345	254,426,582
10	Jyseleca	308	1,444	254,276,580

Top 10 Prescription Drugs by Sales Amount Among Anticancer Drugs

DPC Data (August 2024-July 2025)
	Product Name	Actual Number of Patients	Number of Cases	Total Cost (JPY)
1	Keytruda	18,710	108,725	51,854,988,024
2	Opdivo	12,149	101,875	34,120,137,457
3	Tagrisso	8,333	81,560	28,184,872,080
4	Imfinzi	6,446	31,449	25,122,735,214
5	Tecentriq	5,847	35,160	19,699,593,339
6	Darzquro	3,968	39,330	17,500,021,515
7	Verzenio	7,616	54,567	17,176,624,078
8	Cyramza	6,625	45,608	13,064,260,186
9	Abraxane	15,846	131,269	12,139,933,136
10	Polivy	3,500	13,280	11,688,414,772

Health Insurance Data (July 2024-June 2025)
	Product Name	Actual Number of Patients	Number of Cases	Total Cost (JPY)
1	Keytruda	1,193	6,910	3,291,900,806
2	Verzenio	1,114	7,438	2,671,328,943
3	Opdivo	580	4,779	1,675,888,149
4	Tagrisso	394	3,371	1,467,421,294
5	Enhertu	328	2,205	1,329,087,846
6	Imfinzi	321	1,578	1,256,673,410
7	Alecensa	171	1,129	1,164,073,946
8	Phesgo	614	4,228	1,163,787,112
9	Lynparza	351	2,737	1,147,510,696
10	Cyramza	368	3,127	877,361,158

Note: The above ranking is extracted from health insurance data. Data from the National Health Insurance and Medical Care System for the Elderly are not included.

Databases, data analysis requests, and more.